What is SensArs?
SensArs is a pioneering company at the forefront of neuromodulation technology, dedicated to treating diabetic neuropathy. Their innovative neurostimulation device is engineered to restore foot sensation in individuals with diabetes, thereby substantially mitigating the risks associated with ulcers, falls, and amputations. The company's commitment to advancing patient care is evidenced by its established partnerships with prestigious institutions and a portfolio of numerous awards recognizing its groundbreaking technological contributions.
How much funding has SensArs raised?
SensArs has raised a total of $1.1M across 1 funding round:
Other Financing Round
$1.1M
Other Financing Round (2024): $1.1M with participation from Hth
Key Investors in SensArs
Hth
Health Technology Holding (HTH) is a global investment and advisory firm focused on life science innovations in sectors such as biotech, medtech, drug delivery, and digital health. Established in 2020, HTH actively collaborates with early-stage startups to enhance human health by providing not only capital but also access to a broad network of stakeholders.
What's next for SensArs?
The recent major strategic investment in SensArs signals a pivotal moment for the company, likely enabling accelerated scaling of its operations and further development of its neuromodulation solutions. This capital infusion is expected to bolster market penetration and support ongoing research and development efforts aimed at enhancing the quality of life for individuals affected by diabetic neuropathy. The company's trajectory suggests a strong focus on expanding its reach and solidifying its position as a leader in medical technology for diabetes management.
See full SensArs company page
